This author has yet to write their bio.Meanwhile lets just say that we are proud IDEAL contributed a whooping 60 entries.
According to an EMA press release, the European Medicines Agency in 2014 recommended the highest number of orphan drugs for marketing authorisation in a year. 17 out of 82 medicines that were approved in 2014, are inteded for the treatment of rare diseases. The new medicines for rare diseases include the first medicine for the […]
According to the website RDR Rare Disease Report, “a remarkable 36 orphan drugs were approved for new indications by the U.S. Food and Drug Administration (FDA) in 2014.” The indications addressed by the new therapies include (among others) rare cancers as well as gaucher disease and idiopathic pulmonary fibrosis. This development shows that rare diseases […]
The IDEAL project has been especially mentioned in a recent article of Smith et al. on “Methododolgy of clinical trials for rare diseases” as an example how important the development of novel methodology is to improve the efficiency of rare disease trials.” The paper recognizes that the ongoing research of the IDeAl project is making […]
Franz König is one of the invited panelists at FDA & SCT/QSPI workshop on innovations in the science and practice of clinical trials in Washington today. The panel discussion is part of the session on Rare Diseases, Small Clinical Trials and Rare events. For further information see the sct website. The program of the workshop […]
Piotr Sobczyk now released the R package varclust for dimension reduction via variables clustering. varclust is highly relevant for the identification of genetic pathways. In particular, it achieves the aim of finding the the major regulatory process and identifying the genes that are the triggers behind the whole group. The ease of use is ensured by […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKBy continuing to use the site, you agree to the use of cookies. more information